Coming Off a GLP-1: What Happens When You Stop Semaglutide or Tirzepatide
What the Ozempic, Wegovy, Mounjaro and Zepbound labels say about stopping, missed doses and restarting - and what the withdrawal trials found.
The short version
Ozempic, Wegovy, Mounjaro and Zepbound each have label instructions for a missed dose, but none publishes a taper schedule for stopping on purpose. In randomised trials that switched people to placebo on a set schedule, most of the lost weight came back within a year. The blood-pressure and blood-sugar gains faded too. People with type 2 diabetes have extra reason to plan a change with their prescriber, because the glucose-lowering effect ends when the drug does.
- No label gives a taper schedule for stopping on purpose, only instructions for a missed dose.
- A randomised trial found continuing semaglutide kept losing weight while switching to placebo reversed the trend within weeks.
- A year after stopping semaglutide, one trial found most of the lost weight had come back.
- A tirzepatide withdrawal trial found a similar pattern: regain on placebo, continued loss on the drug.
- Stopping changes blood sugar control in type 2 diabetes, so any change belongs with the prescriber.
Stopping semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) is a different question from missing a dose by accident. The approved labels answer only one of the two directly. This page separates what the labels say from what the withdrawal trials found when researchers switched people to placebo on a fixed schedule and watched what happened.
None of it is instructions to stop or taper on your own. It is context for a conversation with the prescriber managing that treatment.
Missed dose vs. deliberately stopping
The labels cover only the first of these. A missed dose has a defined window for taking it late before you skip it. Deciding to stop treatment altogether has no published schedule.
| Product | Missed-dose window | If several doses in a row are missed |
|---|---|---|
| Ozempic (semaglutide) | Take it within 5 days of the missed dose, otherwise skip it | Label does not give a separate multi-dose restart rule |
| Wegovy (semaglutide) | Take it if the next dose is more than 2 days away, otherwise skip it | Restart the dose escalation at a lower dose |
| Mounjaro (tirzepatide) | Take it within 4 days (96 hours) of the missed dose, otherwise skip it | Label does not give a separate multi-dose restart rule |
| Zepbound (tirzepatide) | Take it within 4 days (96 hours) of the missed dose, otherwise skip it | Label does not give a separate multi-dose restart rule |
Full missed-dose and overdose detail: semaglutide missed dose · tirzepatide missed dose. Titration schedules: semaglutide dosing · tirzepatide dosing.
What the label says about stopping on purpose
Not much. Wegovy’s and Zepbound’s labels describe the weight-management indication as long-term treatment: to reduce excess body weight and maintain that reduction long term. That frames the drug as ongoing management of a chronic condition, not a fixed course with a planned end date. Ozempic’s and Mounjaro’s labels are written around type 2 diabetes management, where treatment duration is likewise set by the condition.
None of the four labels publishes a downward taper. Dose escalation only runs one direction, up toward a maintenance dose, and there is no step-down schedule for coming off.
The one explicit stopping instruction on Ozempic’s label is unrelated to weight or blood sugar. It says to discontinue at least 2 months before a planned pregnancy, because of how long semaglutide stays in the body. Since the label does not say what to expect after an elective stop, the trials are the next place to look.
What the randomised withdrawal trials found
Three trials tested this directly. They randomised people who had already lost weight on a GLP-1 to either keep taking it or switch to placebo, on a fixed schedule, and measured what happened.
STEP 4 ran 803 adults through 20 weeks of open-label semaglutide up to the 2.4 mg maintenance dose. It then randomised them 2:1 to continue semaglutide or switch to placebo for a further 48 weeks. From week 20 to week 68, body weight change was -7.9% in the group that continued versus +6.9% in the group switched to placebo. The estimated difference was -14.8 percentage points. Rubino 2021 - Rubino D, Abrahamsson N, Davies M et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425., in the references below
STEP 1’s trial extension followed people for a year after semaglutide was withdrawn at week 68. By week 120, the former semaglutide group had regained a mean of 11.6 percentage points of body weight. The group on placebo throughout regained 1.9 points. Net weight change from the very start of the trial (week 0) to week 120 was -5.6% for the former semaglutide group versus -0.1% for the placebo group. Most, though not all, of the earlier loss had come back. Blood pressure and HbA1c also drifted back toward baseline over that year off treatment. Wilding 2022 - Wilding JPH, Batterham RL, Davies M et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564., in the references below
SURMOUNT-4 ran the same experiment with tirzepatide. A 36-week open-label lead-in reached an average 20.9% weight reduction. Participants were then randomised to continued tirzepatide or placebo for a further 52 weeks. From randomisation to week 88, weight change was -5.5% in the group that continued versus +14.0% in the group switched to placebo. Aronne 2024 - Aronne LJ, Sattar N, Horn DB et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48., in the references below
Consistent findings across large trials or meta-analyses. Three independent randomised, placebo-controlled withdrawal trials, across two molecules, all pointing the same direction on weight regain after stopping.
The pattern across all three is the same. Continuing the drug held weight loss steady or extended it. Switching to placebo on a fixed schedule reversed a large share of the loss within about a year.
None of the three trials tested a gradual taper against an abrupt stop. They show what happens after stopping on this schedule, not whether tapering changes the outcome.
Blood sugar considerations for type 2 diabetes
The withdrawal trials above enrolled people without diabetes and measured weight. For someone taking Ozempic or Mounjaro to manage type 2 diabetes, stopping changes glycemic control directly, because the glucose-lowering effect ends when the drug does. That is a separate question from weight regain, and it needs its own plan.
It cuts both ways around other diabetes medicines. Both labels warn that combining the GLP-1 with an insulin secretagogue such as a sulfonylurea, or with insulin itself, carries an increased risk of hypoglycemia, including severe hypoglycemia. Both recommend considering a dose reduction of the concomitant insulin or sulfonylurea when starting the GLP-1.
Stopping the GLP-1 later can just as easily call for revisiting that insulin or sulfonylurea dose in the other direction. The medicine that was offsetting some of their glucose-lowering effect is no longer there. The labels route that judgment call to a prescriber. Do not work it out alone against a home glucose meter.
Any change belongs with your prescriber
The labels give a schedule for a missed dose, not for an elective stop. The trials describe an average pattern across hundreds of people on a specific research protocol, not a prediction for one person. Diabetes medicines also interact with each other in ways that argue for supervision in both directions, starting and stopping alike.
None of this page is advice to stop, continue, or taper a GLP-1 on your own schedule. If you are considering a change, bring it to the prescriber managing your treatment. They know your history and your other medicines, and can set a plan that covers both the weight and, if it applies, the diabetes side of stopping.
Related reading
- Semaglutide: the approved label
- Tirzepatide: the approved label
- Semaglutide dosing schedule
- Tirzepatide dosing schedule
- Semaglutide overdose and missed dose
- Tirzepatide overdose and missed dose
Common questions
What happens if I stop taking Ozempic or Wegovy?
The approved labels do not describe a deliberate stop, only a missed dose. In the randomised trials that stopped the drug on a set schedule, people who switched to placebo regained weight over the following months. People who kept taking it continued losing or held steady. Blood pressure and blood sugar measures that had improved also drifted back toward pre-treatment levels. That is not a reason to keep taking a medicine you and your prescriber have decided to stop. It is context for planning that decision with them rather than alone.
Will I gain the weight back after stopping semaglutide or tirzepatide?
In the trials that tested this directly, a large share of the lost weight returned. One extension study found that a year after withdrawing semaglutide, participants had regained roughly two-thirds of the weight they had lost. Their net loss was much smaller than at the end of active treatment. A separate tirzepatide trial found the placebo group regained a substantial share of body weight over a year, while the group that kept taking the drug lost further. Regain was common but not universal, and individual results varied.
Can I just stop my GLP-1 medicine without tapering the dose down?
The approved labels for Ozempic, Wegovy, Mounjaro and Zepbound include no taper schedule for elective discontinuation. Dose escalation only runs upward, toward the maintenance dose, and the labels are silent on stepping back down before stopping. That silence is not a green light to stop on your own schedule. Stopping, changing the dose, or switching medicines are decisions for the prescriber managing your treatment, who can weigh your specific history.
What if I miss a dose of Ozempic, Wegovy, Mounjaro or Zepbound?
Each label gives its own window. Ozempic: take it within 5 days of the missed dose, otherwise skip it and resume the regular weekly schedule. Mounjaro and Zepbound: take it within 4 days (96 hours), otherwise skip it. Wegovy: take it if the next scheduled dose is more than 2 days away, otherwise skip it. If 2 or more consecutive Wegovy doses are missed, the label says to restart the dose escalation at a lower dose. These are missed-dose rules, not instructions for someone who has decided to stop.
Is it safe to stop a GLP-1 medicine if I have type 2 diabetes?
Stopping changes glycemic control, because the glucose-lowering effect ends when the drug does. It matters most for people also taking insulin or a sulfonylurea. The labels already warn that this combination carries a higher risk of hypoglycemia and often calls for a dose adjustment. That adjustment can run in either direction, depending on whether the GLP-1 is being started, adjusted or stopped. The label puts this decision with the clinician managing the diabetes treatment, so do not change it unilaterally.
Do I need to restart at a lower dose if I have missed several doses in a row?
Wegovy's label addresses this directly. After 2 or more consecutive missed doses, it says to restart the dose escalation at a lower dose to reduce the risk of gastrointestinal side effects. Ozempic's and Mounjaro's labels do not spell out the same multi-dose scenario. Either way, restarting after a long gap is a question for the prescriber, who can judge whether re-escalation makes sense in your case.
References (7 sources)
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.
- 1.Rubino D, Abrahamsson N, Davies M et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425.Randomised trialPMID 33755728full text
- 2.Wilding JPH, Batterham RL, Davies M et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564.Randomised trialPMID 35441470full text
- 3.Aronne LJ, Sattar N, Horn DB et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48.Randomised trialPMID 38078870full text
- 4.OZEMPIC (semaglutide) injection - full prescribing information, including missed-dose instructions and the hypoglycemia warning with insulin or sulfonylureas.- DailyMed, National Library of Medicinelabel
- 5.WEGOVY (semaglutide) injection and tablets - full prescribing information, including the missed-dose and reinitiation-after-missed-doses instructions.- DailyMed, National Library of Medicinelabel
- 6.MOUNJARO (tirzepatide) injection - full prescribing information, including missed-dose instructions and the hypoglycemia warning with insulin or sulfonylureas.- DailyMed, National Library of Medicinelabel
- 7.ZEPBOUND (tirzepatide) injection - full prescribing information for the weight-management indication, including missed-dose instructions.- DailyMed, National Library of Medicinelabel